SCHEMBL6047247

SCHEMBL6047247

Nc1nc(C(=O)N2CCC(CCO)CC2)cc2nc(-c3ccco3)nn12

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.54
ADORA1 P30542 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6047236 0.88 ADORA2A (0.58) ADORA2AADORA1
SCHEMBL6047302 0.88 ADORA2A (0.52) ADORA2AADORA1
SCHEMBL6047219 0.87 ADORA2A (0.57) ADORA2AADORA1
SCHEMBL6047235 0.86 ADORA2A (0.56) ADORA2AADORA1
SCHEMBL6047365 0.85 ADORA2A (0.72) ADORA2AADORA1
SCHEMBL6047293 0.85 ADORA2A (0.72) ADORA2AADORA1
SCHEMBL6047220 0.85 ADORA2A (0.72) ADORA2AADORA1
SCHEMBL6047388 0.84 ADORA2A (0.55) ADORA2AADORA1
SCHEMBL6047262 0.84 ADORA2A (0.60) ADORA2A
SCHEMBL6206740 0.84 ADORA2A (0.60) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058320-A1 [1,2,4] Triazolo[1,5-c]pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-03-16 US disclosed
EP-1544200-A1 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058320-A1 [1,2,4] Triazolo[1,5-c]pyrimidine derivatives ADORA2A, ADORA1, ADORA3 ADORA2A 1/4885ADORA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.